[
  {
    "ts": null,
    "headline": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
    "summary": "President Donald Trump’s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system.  While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.”  A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.",
    "url": "https://finnhub.io/api/news?id=bb87f87fa47de290d5a66e6b72d3829b49f8e309d26fc95a8a2d94592ea90561",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745334780,
      "headline": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
      "id": 134038508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "President Donald Trump’s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system.  While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.”  A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.",
      "url": "https://finnhub.io/api/news?id=bb87f87fa47de290d5a66e6b72d3829b49f8e309d26fc95a8a2d94592ea90561"
    }
  },
  {
    "ts": null,
    "headline": "Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for",
    "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=cadfb75df9ecba8f285f1ee1fdde4e0c88f3ff9c1149127089d9d5f092c0a85e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745330458,
      "headline": "Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for",
      "id": 134038509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=cadfb75df9ecba8f285f1ee1fdde4e0c88f3ff9c1149127089d9d5f092c0a85e"
    }
  },
  {
    "ts": null,
    "headline": "Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy",
    "summary": "Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.",
    "url": "https://finnhub.io/api/news?id=fb797e9d859b02cce2cfd30df698c57a5a3a2d8623dade1fe4a1f6047414ee40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745329681,
      "headline": "Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy",
      "id": 134038510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.",
      "url": "https://finnhub.io/api/news?id=fb797e9d859b02cce2cfd30df698c57a5a3a2d8623dade1fe4a1f6047414ee40"
    }
  },
  {
    "ts": null,
    "headline": "Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics",
    "summary": "Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.",
    "url": "https://finnhub.io/api/news?id=9240d1e358074e2506bdda7bf1f494aa338022bf8a26ea8faa6abdee6b27c295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745327719,
      "headline": "Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics",
      "id": 134038511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.",
      "url": "https://finnhub.io/api/news?id=9240d1e358074e2506bdda7bf1f494aa338022bf8a26ea8faa6abdee6b27c295"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?",
    "summary": "Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=fc7284558b260b2aa35915f10fea13d539f12765babd08abe505f1f79771400b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745327160,
      "headline": "Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?",
      "id": 134038512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=fc7284558b260b2aa35915f10fea13d539f12765babd08abe505f1f79771400b"
    }
  },
  {
    "ts": null,
    "headline": "Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?",
    "summary": "Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.",
    "url": "https://finnhub.io/api/news?id=63eea87e4fa375a4c1d969789e3a1911ff93f7c356fb2e66eee99bdc6ea720ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745325000,
      "headline": "Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?",
      "id": 134038513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.",
      "url": "https://finnhub.io/api/news?id=63eea87e4fa375a4c1d969789e3a1911ff93f7c356fb2e66eee99bdc6ea720ba"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Initiates Coverage of AbbVie (ABBV) with Overweight Recommendation",
    "summary": "Cantor Fitzgerald Initiates Coverage of AbbVie (ABBV) with Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=9de59d3da037cd30a2ccd2ad46514dd158d19b4155706f8bd3637fb7a44d1b38",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745323508,
      "headline": "Cantor Fitzgerald Initiates Coverage of AbbVie (ABBV) with Overweight Recommendation",
      "id": 134032747,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9de59d3da037cd30a2ccd2ad46514dd158d19b4155706f8bd3637fb7a44d1b38"
    }
  },
  {
    "ts": null,
    "headline": "Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders",
    "summary": "NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=8e2a715415fd75edf9c6294b3134dc1ef92a1bc85194a78a7cd87964d9e42e5f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745300778,
      "headline": "Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders",
      "id": 134030800,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=8e2a715415fd75edf9c6294b3134dc1ef92a1bc85194a78a7cd87964d9e42e5f"
    }
  }
]